We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Five Serologic Tests Evaluated for Threadworm Infection Follow-Up

By LabMedica International staff writers
Posted on 25 Feb 2015
Print article
Image: Adult female of Strongyloides stercoralis collected in bronchial fluid of a patient with disseminated disease (Photo courtesy of Sacro Cuore Hospital).
Image: Adult female of Strongyloides stercoralis collected in bronchial fluid of a patient with disseminated disease (Photo courtesy of Sacro Cuore Hospital).
Traditional fecal-based methods have poor sensitivity for the detection of Strongyloides stercoralis, therefore are inadequate for post-treatment evaluation of infected patients who should be carefully monitored to exclude the persistence of the infection.

The performance of the five serological tests has been compared for the follow up of patients after treatment, who were infected with S. stercoralis or threadworm, in order to identify if antibody decline could be used a surrogate marker for cure, in addition to negative stools.

Scientists at the Center for Tropical Diseases, Sacro Cuore Hospital (CTD; Verona, Italy) and an international team carried out retrospective study on archived, anonymized sera available at the CTD. Samples were classified according to a composite reference standard, a procedure used for evaluation of diagnostic tests when there is no gold standard: a) positive: positive fecal tests and/or at least 3/5 positive serologic tests; b) negative: negative fecal tests and less than three positive results out of the five serologic tests.

The samples were tested with two commercially-available enzyme-linked immunosorbent assays (ELISA) for Strongyloides (IVD Research; Carlsbad, CA, USA, and Bordier Affinity Products; Crissier, Switzerland), and three noncommercial tests: immunofluorescence antibody test (IFAT), recombinant Strongyloides antigen (NIE) enzyme-linked immunosorbent assay (NIE-ELISA), and the NIE- luciferase immunoprecipitation systems (NIE-LIPS).

A high proportion of samples demonstrated for each test a seroreversion or a relevant decline in optical density/relative light units halved or decreases of at least two titers for IFAT at follow up. The results confirmed by the linear mixed effects model that showed a trend to seroreversion over time for all tests. In particular, IVD-ELISA where almost 90% samples demonstrated relevant decline and almost 87% of IFAT had the best performances. Considering only samples with a complete negativization, NIE-ELISA showed the best performance with 72.5% seroreversion.

The authors that concluded that each of the serology tests considered can be used for monitoring patients who received a treatment for S. stercoralis infection. Serology, in combination with fecal-based methods, should be used as the preferred tool for the follow up. Validation of polymerase chain reaction (PCR) techniques for the follow up might be a useful support for situations of uncertainty such as patients with serology values that do not seem to decrease over time. The study was published on February 10, 2015, in the journal Public Library of Science Neglected Tropical Diseases.

Related Links:

Center for Tropical Diseases
IVD Research
Bordier Affinity Products 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.